A Phase 3 interventional study of Uterine curettage and Chemotherapy in Gestational Trophoblastic Neoplasia, Molar Pregnancy and Gestational Trophoblastic Tumor, Non-Metastatic, sponsored by Brigham and Women's Hospital. Recruiting at 7 sites in Brazil. Open to female participants. Per ClinicalTrials.gov, last updated 2022-05-27.
Sponsored by Brigham and Women's Hospital · Phase 3, Interventional, and Treatment
To evaluate the efficacy and safety of second uterine curettage in patients with low-risk non-metastatic GTN.
This is a randomized, multicenter clinical trial including patients seen at one of 13 gestational trophoblastic disease reference centers in Brazil. Subjects are eligible if they have low-risk gestational trophoblastic neoplasia according to FIGO 2000 criteria and the FIGO/WHO prognostic risk score. The study includes two treatment arms: immediate treatment with single-agent chemotherapy (center choice of agent) or second uterine curettage. The primary outcome is the rate of primary remission. Secondary outcomes are the number of chemotherapy cycles required to achieve remission, rate of primary chemotherapy resistance, rate of relapse, and overall survival.
Exclusion Criteria:
Patients allocated to receive conventional chemotherapy will be treated with methotrexate (1 mg/kg intramuscular) with rescue of folinic acid (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
Drug: Chemotherapy
Patients randomized to undergo a second curettage will undergo manual or electronic vacuum aspiration under ultrasound guidance. Following discharge after the second curettage patients will return to weekly hCG monitoring. If hCG levels are decreasing, patients will remain on weekly hCG follow-up until the first normal hCG (\<5 IU/L) is achieved. Then they will have monthly hCG monitoring for 12 months. If patients do not attain remission and develop persistent GTN as established by FIGO 2000, the tumor will be re-staged and appropriate chemotherapy will be initiated.
Procedure: Uterine curettage
Manual or electric vacuum aspiration under ultrasound guidance.
conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
Remission rate from primary therapy
Undetectable hCG on weekly serum assay for at least three weeks
Time frame: 3 years
Cycles to remission
Total number of cycles of chemotherapy required to attain remission
Time frame: 3 years
Time to remission
Time in days from randomization to remission
Time frame: 3 years
Need for multiagent chemotherapy
Need for progression from single agent to multiagent chemotherapy
Time frame: 3 years
Relapse
Re-elevation of hCG after achieving remission
Time frame: 1 year
Death
Death from any cause
Time frame: 1 year
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital